शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
ALKEMNSEALKEM LABORATORIES LTD.· Pharmaceuticals & BiotechnologyHighNeutral
Announced Fri, 14 Aug, 2026 · 13:45 IST

Alkem Labs Q1 FY27 results: Revenue up 11%, PAT down 22% YoY

ALKEM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-1.5%Reaction day
₹5449.50
prior close
₹5408.00
announcement price
In-mkt
timing
Nifty Midcap 150market-0.5%-1.0% vs market
Pharmaceuticals peers, median of 166sector-0.4%-1.1% vs sector

On the reaction day the stock moved 1.0 pts less than Nifty Midcap 150 and 1.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+0.4
10m
-0.7
15m
-0.6
30m
-3.2
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-1.5-0.5-1.0-0.4-1.1
Next day
-1.4-0.4-1.0-0.3-1.1
2d
+0.5-0.7+1.2-0.6+1.0
3d
-1.2-1.0-0.2-1.4+0.2
4d
-0.9-0.6-0.3-0.8-0.1
5d
-0.9-0.6-0.3-0.4-0.5
1w
-1.9-0.0-1.8-0.9-1.0
15d
-4.8-1.6-3.2+0.0-4.8
1m
-5.3-5.0-0.3-0.1-5.2
2m
-4.7-7.3+2.6-2.6-2.1
3m
—————
UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 166Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Alkem Labs Q1 FY27 (June 2026): consolidated revenue Rs 3,740 crore, up 11% YoY from Rs 3,371 crore. Net profit fell 22% to Rs 521 crore vs Rs 668 crore, mainly on higher tax under the new tax regime. Profit before exceptional items and tax rose slightly to Rs 772 crore. No exceptional items this quarter. Auditors Deloitte issued an unmodified review. Alkem acquired a majority stake in Occlutech Holding AG Switzerland via its medtech arm after quarter end. Prior periods restated for Generic business transfer.

Likely market impact

Revenue grew solidly but PAT fell on higher taxes. New tax regime and medtech acquisition are key watchpoints.